MX2011003304A - Imidazopiridazinacarbonitrilos utiles como inhibidores de cinasa. - Google Patents

Imidazopiridazinacarbonitrilos utiles como inhibidores de cinasa.

Info

Publication number
MX2011003304A
MX2011003304A MX2011003304A MX2011003304A MX2011003304A MX 2011003304 A MX2011003304 A MX 2011003304A MX 2011003304 A MX2011003304 A MX 2011003304A MX 2011003304 A MX2011003304 A MX 2011003304A MX 2011003304 A MX2011003304 A MX 2011003304A
Authority
MX
Mexico
Prior art keywords
cell
identifier
land mobile
mobile network
network
Prior art date
Application number
MX2011003304A
Other languages
English (en)
Spanish (es)
Inventor
Soong-Hoon Kim
Liqi He
Ashvinikumar Gavai
Brian Fink
Libing Chen
Andrew Nation
Yufen Zhao
Litai Zhang
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2011003304A publication Critical patent/MX2011003304A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mobile Radio Communication Systems (AREA)
MX2011003304A 2008-10-09 2009-10-08 Imidazopiridazinacarbonitrilos utiles como inhibidores de cinasa. MX2011003304A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10404508P 2008-10-09 2008-10-09
PCT/US2009/059968 WO2010042699A1 (en) 2008-10-09 2009-10-08 Imidazopyridazinecarbonitriles useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2011003304A true MX2011003304A (es) 2011-04-21

Family

ID=41718919

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011003304A MX2011003304A (es) 2008-10-09 2009-10-08 Imidazopiridazinacarbonitrilos utiles como inhibidores de cinasa.

Country Status (27)

Country Link
US (3) US8252795B2 (enExample)
EP (1) EP2350081B1 (enExample)
JP (1) JP5560278B2 (enExample)
KR (1) KR20110075010A (enExample)
CN (1) CN102245609B (enExample)
AR (1) AR073818A1 (enExample)
AU (1) AU2009302360B2 (enExample)
BR (1) BRPI0920135A2 (enExample)
CA (1) CA2739782A1 (enExample)
CL (1) CL2011000777A1 (enExample)
CO (1) CO6361936A2 (enExample)
CY (1) CY1114539T1 (enExample)
DK (1) DK2350081T3 (enExample)
EA (1) EA018163B1 (enExample)
ES (1) ES2426951T3 (enExample)
HR (1) HRP20130787T1 (enExample)
IL (1) IL211693A (enExample)
MX (1) MX2011003304A (enExample)
NZ (1) NZ591712A (enExample)
PE (1) PE20110411A1 (enExample)
PL (1) PL2350081T3 (enExample)
PT (1) PT2350081E (enExample)
SI (1) SI2350081T1 (enExample)
SM (1) SMT201300109B (enExample)
TW (1) TWI491610B (enExample)
WO (1) WO2010042699A1 (enExample)
ZA (1) ZA201102423B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5394404B2 (ja) * 2008-02-06 2014-01-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用な置換イミダゾピリダジン類
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US9587033B2 (en) 2010-11-15 2017-03-07 University Of Florida Research Foundation, Inc. Therapeutic and diagnostic applications targeting TNK-1
JP2014503521A (ja) 2010-12-17 2014-02-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過増殖性障害の処置におけるmps−1およびtkk阻害剤としての使用のための、イミダゾピラジン類
WO2012080234A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
ES2544609T3 (es) 2010-12-17 2015-09-02 Bayer Intellectual Property Gmbh Imidazopirazinas 2-sustituidas para uso como inhibidores de Mps-1 y TTK en el tratamiento de trastornos hiper-proliferativos
US20140323519A1 (en) * 2011-04-26 2014-10-30 Merck Sharp & Dohme Corp. Heterocyclic compounds as b-raf inhibitors for treatment of cancer
CN104284896B (zh) 2012-03-14 2016-06-01 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
PT3008062T (pt) 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR102782807B1 (ko) 2015-11-18 2025-03-14 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
WO2017223432A1 (en) 2016-06-24 2017-12-28 Polaris Pharmaceuticals Ck2 inhibitors, compositions and methods thereof
RS66420B1 (sr) * 2016-08-10 2025-02-28 Takeda Pharmaceuticals Co Heterociklično jedinjenje
CN110191887B (zh) 2016-11-17 2022-02-18 百时美施贵宝公司 IL-12、IL-23和/或IFN-α的咪唑并哒嗪调节剂
AU2018243770A1 (en) 2017-03-30 2019-09-19 F. Hoffmann-La Roche Ag Isoquinolines as inhibitors of HPK1
CA3079786A1 (en) 2017-10-24 2019-05-02 The Broad Institute, Inc. 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
CN109988150B (zh) 2017-12-29 2022-04-12 江苏中旗科技股份有限公司 N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用
WO2019128871A1 (zh) 2017-12-29 2019-07-04 江苏中旗科技股份有限公司 N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用
EP3719011B1 (en) 2017-12-29 2023-03-29 Jiangsu Flag Chemical Industry Co., Ltd. Pyrazole amide compound having pesticidal activity and use thereof
MX2020007797A (es) * 2018-01-29 2020-09-18 Merck Patent Gmbh Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
BR112021000257A2 (pt) 2018-07-09 2021-04-06 Boehringer Ingelheim Animal Health USA Inc. Compostos heterocíclicos anti-helmínticos
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
JP7526196B2 (ja) * 2019-03-05 2024-07-31 ブリストル-マイヤーズ スクイブ カンパニー Il-12、il-23、および/またはifnアルファ応答の調節剤として有用なイミダゾピリダジン化合物
PE20220281A1 (es) 2019-03-19 2022-02-25 Boehringer Ingelheim Animal Health Usa Inc Compuestos de aza-benzotiofeno y aza-benzofurano como antihelminticos
MA55751A (fr) 2019-04-24 2022-03-02 Bayer Ag Composés de 4h-pyrrolo[3,2-c]pyridin-4-one
EP3958865B1 (en) 2019-04-24 2025-12-10 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
CA3137610A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
EP4126861B1 (en) 2020-03-31 2025-06-18 Bayer Aktiengesellschaft 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer
WO2021242581A1 (en) 2020-05-29 2021-12-02 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic heterocyclic compounds
IL304906A (en) * 2021-02-03 2023-10-01 Sanofi Sa DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2023073641A1 (en) 2021-11-01 2023-05-04 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic pyrrolopyridazine compounds
US20250163063A1 (en) * 2022-01-25 2025-05-22 Kinnate Biopharma Inc. Inhibitors of cdk4/6 kinase
WO2024039767A1 (en) * 2022-08-18 2024-02-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Imidazo[1,2-b]pyridazine inhibitors of cyclin-dependent kinases
CN115947756B (zh) * 2022-12-13 2025-08-01 西湖大学 一种芳基卤代物和多氟烷基醇直接偶联合成多氟烷基芳基醚的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0923582B1 (en) 1996-08-28 2006-09-20 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
ES2244613T3 (es) 2000-04-27 2005-12-16 Astellas Pharma Inc. Derivados de imidazopiridina.
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
ES2624353T3 (es) 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
KR20060110344A (ko) * 2003-12-31 2006-10-24 쉐링-프라우 리미티드 이미다조[1,2-b]피리다진 유도체를 사용하여 동물에서기생충을 방제하는 방법
CA2555263A1 (en) 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
CN101048158A (zh) * 2004-08-13 2007-10-03 健泰科生物技术公司 利用atp的酶的噻唑-类抑制剂
US20080167314A1 (en) * 2004-12-28 2008-07-10 Osamu Uchikawa Condensed Imidazole Compound And Use Thereof
AR056191A1 (es) 2005-08-23 2007-09-26 Idenix Phatmaceuticals Inc Anillo de nucleosidos de siete miembros como inhibidores de la replica viral, metodos para su sintesis, composiciones farmaceuticas que los contienen y su uso en el tratamiento de infecciones con virus de la familia flaviviridae
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
BRPI0714665A2 (pt) * 2006-08-04 2012-03-13 Takeda Pharmaceutical Company Limited Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
EP2063962A2 (en) 2006-09-07 2009-06-03 Biogen Idec MA Inc. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
WO2008029152A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
EP1911451A1 (en) * 2006-10-10 2008-04-16 INSERM (Institut National de la Santé et de la Recherche Medicale) Protein-kinase CK2 inhibitors and their therapeutic applications
US20090318410A1 (en) * 2006-10-30 2009-12-24 Novartis Ag Imidazopyridazines as lipid kinase inhibitors
EA200901488A1 (ru) * 2007-05-09 2010-04-30 Новартис Аг Замещенные имидазолопиридазины, как ингибиторы липидкиназы
JP5394404B2 (ja) * 2008-02-06 2014-01-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用な置換イミダゾピリダジン類
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈

Also Published As

Publication number Publication date
BRPI0920135A2 (pt) 2019-09-24
US8252795B2 (en) 2012-08-28
EA018163B1 (ru) 2013-05-30
CA2739782A1 (en) 2010-04-15
DK2350081T3 (da) 2013-10-14
PT2350081E (pt) 2013-09-24
TWI491610B (zh) 2015-07-11
PE20110411A1 (es) 2011-06-22
CN102245609A (zh) 2011-11-16
KR20110075010A (ko) 2011-07-05
JP5560278B2 (ja) 2014-07-23
SMT201300109B (it) 2013-11-08
HRP20130787T1 (en) 2013-09-30
AU2009302360B2 (en) 2014-12-11
PL2350081T3 (pl) 2013-10-31
US9371328B2 (en) 2016-06-21
JP2012505235A (ja) 2012-03-01
US20100113458A1 (en) 2010-05-06
CO6361936A2 (es) 2012-01-20
AU2009302360A1 (en) 2010-04-15
WO2010042699A1 (en) 2010-04-15
EA201100580A1 (ru) 2011-10-31
ZA201102423B (en) 2012-09-26
NZ591712A (en) 2012-10-26
IL211693A (en) 2015-06-30
CL2011000777A1 (es) 2011-08-12
US20120283241A1 (en) 2012-11-08
TW201018686A (en) 2010-05-16
EP2350081A1 (en) 2011-08-03
AR073818A1 (es) 2010-12-01
CY1114539T1 (el) 2016-10-05
EP2350081B1 (en) 2013-07-03
US20140179674A1 (en) 2014-06-26
ES2426951T3 (es) 2013-10-25
IL211693A0 (en) 2011-06-30
CN102245609B (zh) 2016-03-09
SI2350081T1 (sl) 2013-11-29
HK1154002A1 (en) 2012-04-13

Similar Documents

Publication Publication Date Title
MX2011003304A (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de cinasa.
CN105025396B (zh) 实现专网与公网对讲机通信的方法、系统及集群云基站
US20140370890A1 (en) Method and apparatus for access class barring
CA2739865C (en) Method for operating a closed subscriber group (csg) cell for open network access
RU2014102240A (ru) Система мобильной связи
KR101122189B1 (ko) 비공개 가입자 그룹 아이디 비교를 줄이기 위한 방법
WO2008106360A3 (en) Femtocell integration into the macro network
WO2008134281A3 (en) Wireless communication method and apparatus for performing home node-b identification and access restriction
CN101895929A (zh) 集成的毫微微蜂窝和wlan接入点
US8306559B2 (en) Method and apparatus for paging optimization of base station supporting hybrid cell
CN102378260A (zh) 一种移动负载均衡实现方法和装置
CA2729632C (en) Method for defining a range for closed subscriber group identities for an open network access point
WO2010069240A1 (zh) 移动终端接入开放模式家庭基站的方法及系统
CN102857878B (zh) 一种集群建立方法及系统及网络侧设备及终端
US20230319756A1 (en) Disaster roaming for plmn
CN104168643A (zh) 驻留处理方法及装置
WO2005055633A3 (de) Verfahren zum anmelden eines kommunikationsendgerätes in einem drahtlosen lokalen netzwerk
CN102612114B (zh) 标识更新处理方法、家庭基站、网关和接入网系统
MX2015002154A (es) Procedimiento de transmision de informacion de enlazamiento troncal, y correspondientes terminal y nodo de acceso de enlazamiento troncal.
CN105721270B (zh) 一种集群通信虚拟网的控制方法
CN101674539A (zh) 一种信息推送和呼叫转接的方法、系统及装置
CN102547696A (zh) 毫微微小区基站中用于通信的方法和装置

Legal Events

Date Code Title Description
FG Grant or registration